8
Participants
Start Date
October 29, 2014
Primary Completion Date
January 30, 2015
Study Completion Date
February 9, 2015
Unlabeled ertugliflozin for oral use
15 mg oral (3 x 5 mg tablets)
14^C-labeled ertugliflozin for IV use
100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
14^C-labeled ertugliflozin for oral use
100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
Collaborators (1)
Pfizer
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY